array(40) {
  [0]=>
  string(4) "1849"
  ["article_id"]=>
  string(4) "1849"
  [1]=>
  string(66) "Pre-Filled Syringes - Chemical Compatibility and Design Strategies"
  ["article_title"]=>
  string(66) "Pre-Filled Syringes - Chemical Compatibility and Design Strategies"
  [2]=>
  string(150) "At SMi’s 2019 Pre-Filled Syringes East Coast USA Conference, industry leaders will meet in Boston to share their insights on best design practic"
  ["short_description"]=>
  string(150) "At SMi’s 2019 Pre-Filled Syringes East Coast USA Conference, industry leaders will meet in Boston to share their insights on best design practic"
  [3]=>
  string(584) "At SMi’s 2019 Pre-Filled Syringes East Coast USA Conference, industry leaders will meet in Boston to share their insights on best design practice, drug compatibility within the whole supplier chain and challenges with manufacturing and drug delivery. Key highlights include:Cyclo Olefin Polymer (COP) – technical data update• Key properties of COP• Case study. Biologics formulation for COP syringe optimized to eliminating use of surfactant• Case study. Study on protein adsorption/aggregation – COP vs glass• Case...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(584) "At SMi’s 2019 Pre-Filled Syringes East Coast USA Conference, industry leaders will meet in Boston to share their insights on best design practice, drug compatibility within the whole supplier chain and challenges with manufacturing and drug delivery. Key highlights include:Cyclo Olefin Polymer (COP) – technical data update• Key properties of COP• Case study. Biologics formulation for COP syringe optimized to eliminating use of surfactant• Case study. Study on protein adsorption/aggregation – COP vs glass• Case...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(97) "http://www.realwire.com/releases/Pre-Filled-Syringes-Chemical-Compatibility-and-Design-Strategies"
  ["blog_url"]=>
  string(97) "http://www.realwire.com/releases/Pre-Filled-Syringes-Chemical-Compatibility-and-Design-Strategies"
  [15]=>
  string(19) "2019-02-27 22:48:00"
  ["add_date"]=>
  string(19) "2019-02-27 22:48:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-22 13:42:54"
  ["create_at"]=>
  string(19) "2019-04-22 13:42:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1805"
  ["article_id"]=>
  string(4) "1805"
  [1]=>
  string(51) "Anthony Collins Solicitors Opts For Zylpha Bundling"
  ["article_title"]=>
  string(51) "Anthony Collins Solicitors Opts For Zylpha Bundling"
  [2]=>
  string(150) "Award-winning law firm, Anthony Collins Solicitors, has chosen Zylpha’s bundling for legal and court documents. The solution will be used in con"
  ["short_description"]=>
  string(150) "Award-winning law firm, Anthony Collins Solicitors, has chosen Zylpha’s bundling for legal and court documents. The solution will be used in con"
  [3]=>
  string(578) "Award-winning law firm, Anthony Collins Solicitors, has chosen Zylpha’s bundling for legal and court documents. The solution will be used in conjunction with the practice’s iManage case management software.With high-quality support for a range of specialist sectors – charities, education, health and social care, social housing, local government, social business, and private individuals – efficient document management systems are crucial to the smooth running of the practice. One element of this is legal document bundling,...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(578) "Award-winning law firm, Anthony Collins Solicitors, has chosen Zylpha’s bundling for legal and court documents. The solution will be used in conjunction with the practice’s iManage case management software.With high-quality support for a range of specialist sectors – charities, education, health and social care, social housing, local government, social business, and private individuals – efficient document management systems are crucial to the smooth running of the practice. One element of this is legal document bundling,...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(84) "http://www.realwire.com/releases/Anthony-Collins-Solicitors-Opts-For-Zylpha-Bundling"
  ["blog_url"]=>
  string(84) "http://www.realwire.com/releases/Anthony-Collins-Solicitors-Opts-For-Zylpha-Bundling"
  [15]=>
  string(19) "2019-02-27 19:37:00"
  ["add_date"]=>
  string(19) "2019-02-27 19:37:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-01 11:23:47"
  ["create_at"]=>
  string(19) "2019-04-01 11:23:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1949"
  ["article_id"]=>
  string(4) "1949"
  [1]=>
  string(161) "Bayer Completes Rolling Submission of NDA for Investigational Drug Darolutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)"
  ["article_title"]=>
  string(161) "Bayer Completes Rolling Submission of NDA for Investigational Drug Darolutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)"
  [2]=>
  string(150) "WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U."
  ["short_description"]=>
  string(150) "WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U."
  [3]=>
  string(249) "WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug darolutamide. The submission,..."
  ["description"]=>
  string(249) "WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug darolutamide. The submission,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(259) "https://www.drugs.com/nda/darolutamide_190227.html?utm_source=ddc&utm_medium=rss&utm_campaign=Bayer+Completes+Rolling+Submission+of+NDA+for+Investigational+Drug+Darolutamide+for+the+Treatment+of+Non-Metastatic+Castration-Resistant+Prostate+Cancer+%28nmCRPC%29"
  ["blog_url"]=>
  string(259) "https://www.drugs.com/nda/darolutamide_190227.html?utm_source=ddc&utm_medium=rss&utm_campaign=Bayer+Completes+Rolling+Submission+of+NDA+for+Investigational+Drug+Darolutamide+for+the+Treatment+of+Non-Metastatic+Castration-Resistant+Prostate+Cancer+%28nmCRPC%29"
  [15]=>
  string(19) "2019-02-27 13:02:55"
  ["add_date"]=>
  string(19) "2019-02-27 13:02:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1950"
  ["article_id"]=>
  string(4) "1950"
  [1]=>
  string(158) "Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma"
  ["article_title"]=>
  string(158) "Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma"
  [2]=>
  string(150) "NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced "
  ["short_description"]=>
  string(150) "NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced "
  [3]=>
  string(250) "NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to..."
  ["description"]=>
  string(250) "NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(249) "https://www.drugs.com/nda/selinexor_190227.html?utm_source=ddc&utm_medium=rss&utm_campaign=Karyopharm+Announces+Outcome+of+FDA+Advisory+Committee+Meeting+Reviewing+Selinexor+for+the+Treatment+of+Patients+with+Triple+Class+Refractory+Multiple+Myeloma"
  ["blog_url"]=>
  string(249) "https://www.drugs.com/nda/selinexor_190227.html?utm_source=ddc&utm_medium=rss&utm_campaign=Karyopharm+Announces+Outcome+of+FDA+Advisory+Committee+Meeting+Reviewing+Selinexor+for+the+Treatment+of+Patients+with+Triple+Class+Refractory+Multiple+Myeloma"
  [15]=>
  string(19) "2019-02-27 13:02:06"
  ["add_date"]=>
  string(19) "2019-02-27 13:02:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2386"
  ["article_id"]=>
  string(4) "2386"
  [1]=>
  string(57) "MDISS Extends ISA Guidelines to Connected Medical Devices"
  ["article_title"]=>
  string(57) "MDISS Extends ISA Guidelines to Connected Medical Devices"
  [2]=>
  string(153) "&#nl        BRONX, NY—The Medical Device Innovation, Safety and Security Consortium has announced it is developing a set of recommended practices a"
  ["short_description"]=>
  string(153) "&#nl        BRONX, NY—The Medical Device Innovation, Safety and Security Consortium has announced it is developing a set of recommended practices a"
  [3]=>
  string(360) "&#nl        
BRONX, NY—The Medical Device Innovation, Safety and Security Consortium has announced it is developing a set of recommended practices and profiles for securing medical systems based on the normative requirements in the widely used ISA/IEC 62443 series of standards for industrial automation and control systems cybersecurity.
&#nl      "
  ["description"]=>
  string(360) "&#nl        
BRONX, NY—The Medical Device Innovation, Safety and Security Consortium has announced it is developing a set of recommended practices and profiles for securing medical systems based on the normative requirements in the widely used ISA/IEC 62443 series of standards for industrial automation and control systems cybersecurity.
&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(100) "https://www.assemblymag.com/articles/94775-mdiss-extends-isa-guidelines-to-connected-medical-devices"
  ["blog_url"]=>
  string(100) "https://www.assemblymag.com/articles/94775-mdiss-extends-isa-guidelines-to-connected-medical-devices"
  [15]=>
  string(19) "2019-02-26 13:00:00"
  ["add_date"]=>
  string(19) "2019-02-26 13:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1951"
  ["article_id"]=>
  string(4) "1951"
  [1]=>
  string(139) "Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis"
  ["article_title"]=>
  string(139) "Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis"
  [2]=>
  string(150) "DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced tha"
  ["short_description"]=>
  string(150) "DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced tha"
  [3]=>
  string(247) "DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application..."
  ["description"]=>
  string(247) "DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(229) "https://www.drugs.com/nda/vumerity_190225.html?utm_source=ddc&utm_medium=rss&utm_campaign=Alkermes+and+Biogen+Announce+U.S.+Food+and+Drug+Administration+Acceptance+of+Diroximel+Fumarate+New+Drug+Application+for+Multiple+Sclerosis"
  ["blog_url"]=>
  string(229) "https://www.drugs.com/nda/vumerity_190225.html?utm_source=ddc&utm_medium=rss&utm_campaign=Alkermes+and+Biogen+Announce+U.S.+Food+and+Drug+Administration+Acceptance+of+Diroximel+Fumarate+New+Drug+Application+for+Multiple+Sclerosis"
  [15]=>
  string(19) "2019-02-25 14:02:52"
  ["add_date"]=>
  string(19) "2019-02-25 14:02:52"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2135"
  ["article_id"]=>
  string(4) "2135"
  [1]=>
  string(80) "Exact Sciences Eyes Cologuard Market Expansion After “Landmark Year”"
  ["article_title"]=>
  string(80) "Exact Sciences Eyes Cologuard Market Expansion After “Landmark Year”"
  [2]=>
  string(150) "[Updated 2/22/19, 2:42 pm CT. See below.] Exact Sciences screened 934,000 patients for colorectal cancer in 2018 using its stool-based diagnostic test"
  ["short_description"]=>
  string(150) "[Updated 2/22/19, 2:42 pm CT. See below.] Exact Sciences screened 934,000 patients for colorectal cancer in 2018 using its stool-based diagnostic test"
  [3]=>
  string(364) "[Updated 2/22/19, 2:42 pm CT. See below.] Exact Sciences screened 934,000 patients for colorectal cancer in 2018 using its stool-based diagnostic test, Cologuard, resulting in a 71 percent surge in annual revenue to $454.5 million, the company announced Thursday. Exact (NASDAQ: EXAS), which relocated from the Boston area to Madison, WI, in 2009, is one […]"
  ["description"]=>
  string(364) "[Updated 2/22/19, 2:42 pm CT. See below.] Exact Sciences screened 934,000 patients for colorectal cancer in 2018 using its stool-based diagnostic test, Cologuard, resulting in a 71 percent surge in annual revenue to $454.5 million, the company announced Thursday. Exact (NASDAQ: EXAS), which relocated from the Boston area to Madison, WI, in 2009, is one […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/1NI5epHbBS0/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/1NI5epHbBS0/"
  [15]=>
  string(19) "2019-02-23 00:51:21"
  ["add_date"]=>
  string(19) "2019-02-23 00:51:21"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2136"
  ["article_id"]=>
  string(4) "2136"
  [1]=>
  string(62) "WI Watchlist: Rockwell, Wellbe, Generac, API Healthcare & More"
  ["article_title"]=>
  string(62) "WI Watchlist: Rockwell, Wellbe, Generac, API Healthcare & More"
  [2]=>
  string(150) "Here’s a roundup of recent news from Wisconsin’s high-tech industries: —Rockwell Automation (NYSE: ROK), the Milwaukee-based seller "
  ["short_description"]=>
  string(150) "Here’s a roundup of recent news from Wisconsin’s high-tech industries: —Rockwell Automation (NYSE: ROK), the Milwaukee-based seller "
  [3]=>
  string(402) "Here’s a roundup of recent news from Wisconsin’s high-tech industries: —Rockwell Automation (NYSE: ROK), the Milwaukee-based seller of hardware and software that enables industrial automation, is forming a joint venture with Houston-based Schlumberger (NYSE: SLB), a maker of products for drilling and other tasks in the oil and gas industry. The new venture, called Sensia, […]"
  ["description"]=>
  string(402) "Here’s a roundup of recent news from Wisconsin’s high-tech industries: —Rockwell Automation (NYSE: ROK), the Milwaukee-based seller of hardware and software that enables industrial automation, is forming a joint venture with Houston-based Schlumberger (NYSE: SLB), a maker of products for drilling and other tasks in the oil and gas industry. The new venture, called Sensia, […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/mQ8VbFlNG0E/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/mQ8VbFlNG0E/"
  [15]=>
  string(19) "2019-02-22 22:07:56"
  ["add_date"]=>
  string(19) "2019-02-22 22:07:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2190"
  ["article_id"]=>
  string(4) "2190"
  [1]=>
  string(78) "Pfizer receives European approval for Avastin biosimilar Zirabev (bevacizumab)"
  ["article_title"]=>
  string(78) "Pfizer receives European approval for Avastin biosimilar Zirabev (bevacizumab)"
  [2]=>
  string(152) "Pfizer Inc. announced the European Commission (EC) has approved Zirabev, a biosimilar to Roche/Genentech’s Avastin.  Zirabev is approved for th"
  ["short_description"]=>
  string(152) "Pfizer Inc. announced the European Commission (EC) has approved Zirabev, a biosimilar to Roche/Genentech’s Avastin.  Zirabev is approved for th"
  [3]=>
  string(751) "Pfizer Inc. announced the European Commission (EC) has approved Zirabev, a biosimilar to Roche/Genentech’s Avastin.  Zirabev is approved for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix. “Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said […]"
  ["description"]=>
  string(751) "Pfizer Inc. announced the European Commission (EC) has approved Zirabev, a biosimilar to Roche/Genentech’s Avastin.  Zirabev is approved for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix. “Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "43"
  ["rss_id"]=>
  string(2) "43"
  [14]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/zkTgeGxGw0o/"
  ["blog_url"]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/zkTgeGxGw0o/"
  [15]=>
  string(19) "2019-02-21 14:58:11"
  ["add_date"]=>
  string(19) "2019-02-21 14:58:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:41"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2417"
  ["article_id"]=>
  string(4) "2417"
  [1]=>
  string(50) "What if you could diagnose diseases with a tampon?"
  ["article_title"]=>
  string(50) "What if you could diagnose diseases with a tampon?"
  [2]=>
  string(163) "Women’s health care is often treated as all about reproduction. Some “femtech” startups are exploring the innovations that get overlooked as a r"
  ["short_description"]=>
  string(163) "Women’s health care is often treated as all about reproduction. Some “femtech” startups are exploring the innovations that get overlooked as a r"
  [3]=>
  string(169) "Women’s health care is often treated as all about reproduction. Some “femtech” startups are exploring the innovations that get overlooked as a result."
  ["description"]=>
  string(169) "Women’s health care is often treated as all about reproduction. Some “femtech” startups are exploring the innovations that get overlooked as a result."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "103"
  ["rss_id"]=>
  string(3) "103"
  [14]=>
  string(97) "https://www.technologyreview.com/s/612905/what-if-you-could-diagnose-endometriosis-with-a-tampon/"
  ["blog_url"]=>
  string(97) "https://www.technologyreview.com/s/612905/what-if-you-could-diagnose-endometriosis-with-a-tampon/"
  [15]=>
  string(19) "2019-02-18 20:00:00"
  ["add_date"]=>
  string(19) "2019-02-18 20:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1850"
  ["article_id"]=>
  string(4) "1850"
  [1]=>
  string(152) "Senior Experts from WHO, HPRA, Wellcome Trust, Centauri Therapeutics to present at 21st Annual Superbugs & Superdrugs Conference in 4 weeks’ time"
  ["article_title"]=>
  string(152) "Senior Experts from WHO, HPRA, Wellcome Trust, Centauri Therapeutics to present at 21st Annual Superbugs & Superdrugs Conference in 4 weeks’ time"
  [2]=>
  string(154) "In just 4 weeks’ time, SMi's 21st Annual Superbugs & Superdrugs Conference will kick off in London, setting out to provide an international "
  ["short_description"]=>
  string(154) "In just 4 weeks’ time, SMi's 21st Annual Superbugs & Superdrugs Conference will kick off in London, setting out to provide an international "
  [3]=>
  string(571) "In just 4 weeks’ time, SMi's 21st Annual Superbugs & Superdrugs Conference will kick off in London, setting out to provide an international audience with key updates on the latest developments in combating antibiotic resistance, including the processes and strategies pharmaceuticals use to develop novel therapeutics that utilise alternative mechanisms to treat multi-drug resistant infections.In the run up to the conference, SMi caught up with this year’s co-chair Lloyd Czaplewski, Director at Chemical Biology Ventures,...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(571) "In just 4 weeks’ time, SMi's 21st Annual Superbugs & Superdrugs Conference will kick off in London, setting out to provide an international audience with key updates on the latest developments in combating antibiotic resistance, including the processes and strategies pharmaceuticals use to develop novel therapeutics that utilise alternative mechanisms to treat multi-drug resistant infections.In the run up to the conference, SMi caught up with this year’s co-chair Lloyd Czaplewski, Director at Chemical Biology Ventures,...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(106) "http://www.realwire.com/releases/Senior-Experts-to-present-at-21st-Annual-Superbugs--Superdrugs-Conference"
  ["blog_url"]=>
  string(106) "http://www.realwire.com/releases/Senior-Experts-to-present-at-21st-Annual-Superbugs--Superdrugs-Conference"
  [15]=>
  string(19) "2019-02-18 16:30:00"
  ["add_date"]=>
  string(19) "2019-02-18 16:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-22 13:42:54"
  ["create_at"]=>
  string(19) "2019-04-22 13:42:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1665"
  ["article_id"]=>
  string(4) "1665"
  [1]=>
  string(49) "Trajenta meets primary endpoint in CAROLINA trial"
  ["article_title"]=>
  string(49) "Trajenta meets primary endpoint in CAROLINA trial"
  [2]=>
  string(154) "Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with ty"
  ["short_description"]=>
  string(154) "Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with ty"
  [3]=>
  string(193) "Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk."
  ["description"]=>
  string(193) "Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(89) "http://www.pharmatimes.com/news/trajenta_meets_primary_endpoint_in_carolina_trial_1278422"
  ["blog_url"]=>
  string(89) "http://www.pharmatimes.com/news/trajenta_meets_primary_endpoint_in_carolina_trial_1278422"
  [15]=>
  string(19) "2019-02-15 19:45:50"
  ["add_date"]=>
  string(19) "2019-02-15 19:45:50"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}